公开(公告)号：EP4346402A1

公开(公告)日：2024-04-10

申请号：EP22814638.7

申请日：2022-03-08

Applicant: University Health Network

Inventor： LIU, Mingyao ,  KESHAVJEE, Shafique ,  CYPEL, Marcelo

IPC: A01N1/02

公开(公告)号：EP4118426A1

公开(公告)日：2023-01-18

申请号：EP21767555.2

申请日：2021-03-15

Applicant: University Health Network

Inventor： SAGE, Andrew ,  VALERO, Jerome ,  DEL SORBO, Lorenzo ,  CYPEL, Marcelo ,  WANG, Bo ,  KESHAVJEE, Shafique

IPC: G01N33/48 ,  G01N33/53 ,  G01N33/543 ,  G16H50/30

公开(公告)号：EP3653724A9

公开(公告)日：2021-02-24

申请号：EP19197128.2

申请日：2014-02-20

Applicant: University Health Network

Inventor： KESHAVJEE, Shaf ,  LIU, Mingyao ,  CYPEL, Marcelo

IPC: C12Q1/68 ,  G01N33/48 ,  G01N33/53 ,  C12Q1/6883

Abstract: Methods for assaying a donor lung for chronic allograft lung dysfunction (CLAD) optionally bronchiolitis obliterans syndrome (BOS) subtype or restrictive allograft syndrome (RAS) subtype of CLAD or risk of developing BOS subtype or RAS subtype CLAD post-transplant, the method comprising:
a. measuring a normalized expression level of an RNA transcript of IL-6 or an expression product thereof in a sample of the donor lung pre-transplant or a normalized expression level of one or more S100 protein, optionally S100A8 and/or S100A9, polypeptide expression product in a sample from the donor lung post-transplant;
b. assessing the likelihood of the donor lung developing BOS subtype CLAD or RAS subtype CLAD post-transplant based on said IL-6, S100, optionally S100A8 and/or S100A9, expression level wherein IL-6 expression level is positively correlated with an increased likelihood of developing BOS post-transplant, S100A8 expression level is positively correlated with having or having an increased likelihood of developing RAS and/or BOS subtype CLAD, and S100A9 is positively correlated with having and having an increased likelihood of developing RAS subtype CLAD.

公开(公告)号：EP2959292B1

公开(公告)日：2020-09-30

申请号：EP14754767.3

申请日：2014-02-20

Applicant: University Health Network

Inventor： KESHAVJEE, Shaf ,  LIU, Mingyao ,  CYPEL, Marcelo

IPC: G01N33/68

公开(公告)号：EP3606564A1

公开(公告)日：2020-02-12

申请号：EP18780312.7

申请日：2018-03-29

Applicant: University Health Network ,  Bagnato, Vanderlei, Salvador

Inventor： BAGNATO, Vanderlei Salvador ,  CYPEL, Marcelo ,  KESHAVJEE, Shafique ,  WADDELL, Thomas Kenneth ,  GALASSO, Marcos Theophilo

IPC: A61L2/08 ,  A61L2/10 ,  B01L3/00

公开(公告)号：EP2959292A1

公开(公告)日：2015-12-30

申请号：EP14754767.3

申请日：2014-02-20

Applicant: University Health Network

Inventor： KESHAVJEE, Shaf ,  LIU, Mingyao ,  CYPEL, Marcelo

IPC: G01N33/48 ,  G01N33/483 ,  G01N33/53 ,  G01N33/543

CPC classification number: G01N33/6884 ,  G01N33/68 ,  G01N2333/5754 ,  G01N2800/245 ,  G16B35/00 ,  G16C20/60

Abstract: A method of classifying a lung graft subjected to normothermic ex vivo lung perfusion (EVLP), during perfusion and/or after perfusion, the method comprising: a) collecting a test sample from the lung graft; b) measuring a polypeptide level of a negative transplant predictor gene product selected from CCG predictor gene products M-CSF, IL-8 SCGF-beta, GRO-alpha, G-CSF, MIP-1 alpha, and/or MIP-1beta, endothelin predictor gene products endothelin 1 (ET-1) and/or big ET-1, and/or apoptosis predictor gene products cytokeratin 18 (CK-18), caspase 3 and/or HMGB-1 in the sample and/or determining a metabolite profile of the sample for lung grafts that are from donors where the death was due to cardiac death (DCD); c) identifying the graft as a good candidate for transplant or a poor candidate for transplant wherein an increased polypeptide level of one or more negative transplant outcome predictor gene products compared to an outcome control or a reference metabolic profile is indicative the graft is a poor candidate for transplant.